Holen Sie sich die Stockscreener-App
2.16
1.82%
-0.04
Handel nachbörslich:
2.14
-0.02
-0.93%
Nls Pharmaceutics Ltd Aktie (NLSP) Neueste Nachrichten
What analysts say about NLS Pharmaceutics AG Equity Warrant stockTremendous growth opportunities - Autocar Professional
Is NLS Pharmaceutics AG a good long term investmentConsistently high returns - jammulinksnews.com
Is NLS Pharmaceutics AG Equity Warrant a good long term investmentPhenomenal capital gains - jammulinksnews.com
NLS Pharmaceutics Amends Merger Agreement with Kadimastem - TipRanks
What risks could impact NLS Pharmaceutics AG Equity Warrant stock performanceMassive Upside Selection - Newser
How NLS Pharmaceutics AG stock reacts to Fed policy changesCapital Protected Stock Selections - Newser
NLS Pharma's Diabetes Treatment Project Gets Fresh Funding Boost From US-Israel Foundation - 富途牛牛
NLS Pharmaceutics Advances iTOL-102 Diabetes Program with BIRD Foundation Support - TipRanks
Bird Foundation Approves Additional Milestone Payment to Kadimastem and Itolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy - MarketScreener
NLS Pharmaceutics Highlights Continued Progress in ITOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and ITolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy - 富途牛牛
Why NLS Pharmaceutics AG Equity Warrant stock attracts strong analyst attentionFree Smart Money Stock Analysis - Newser
How NLS Pharmaceutics AG stock performs during market volatilityRapid Gain Targets - Newser
What makes NLS Pharmaceutics AG stock price move sharplyHigh Confidence Trade Setups - Newser
What makes NLS Pharmaceutics AG Equity Warrant stock price move sharplyElite Stock Shortlist - Newser
NLS Pharmaceutics (NASDAQ:NLSP) Upgraded at Wall Street Zen - Defense World
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - Newswire :) Press Release Distribution
NLS Pharmaceutics Gains Shareholder Approval for Strategic Agenda - The Globe and Mail
Why Did NLS Pharmaceutics Soar 13.79%? - AInvest
NLS Pharmaceutics and Kadimastem Closes $1 Million Equity Financing - citybiz
NLS Pharmaceutics Secures $1 Million Through Equity Financing Amendment - TipRanks
NLS Pharmaceutics Soars 10.04% Pre-Market on Investor Optimism - AInvest
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing - PR Newswire
NLS Pharmaceutics Announces Strategic Merger and Financing Milestones - TipRanks
NLS Pharmaceutics CEO Issues Letter to Shareholders - marketscreener.com
NLS Pharmaceutics Transforms: $25M Backing Powers Merger Deal as Company Goes Debt-Free - Stock Titan
NLS Pharmaceutics Announces June 2025 Shareholders’ Meeting Amid Financial Losses - TipRanks
Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Decreases By 56.6% - Defense World
NLS Pharmaceutics to present Mazindol study at ASCP Meeting By Investing.com - Investing.com South Africa
NLS Pharmaceutics to present Mazindol study at ASCP Meeting - Investing.com Australia
NLS Pharmaceutics (NLSP) to Showcase Promising Data on Mazindol ER | NLSP Stock News - GuruFocus
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Ma - GuruFocus
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting - Nasdaq
NLS Pharmaceutics (NASDAQ:NLSP) Trading Down 0.6% – Should You Sell? - Defense World
NLS Pharmaceutics Extends Merger Agreement with Kadimastem - TipRanks
NLSPNls Pharmaceutics Ltd Latest Stock News & Market Updates - Stock Titan
NLS Pharmaceutics Delays Yearly Report Filing - TipRanks
NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering - ACCESS Newswire
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - ACCESS Newswire
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - ACCESS Newswire
NLS Pharmaceutics Announces Board Resignation Amid Restructuring Efforts - TipRanks
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (PR Newswire) - Aktiellt
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS (PR Newswire) - Aktiellt
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com
NLS Pharmaceutics (NLSP): Promising Preclinical Results for Mazi - GuruFocus
NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks
Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - Quantisnow
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models (PR Newswire) - Aktiellt
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - ADVFN
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):